Amendment to exclusive patent, know-how and technology license to make, have made, develop, research, improve, use, process, offer, import, sell and distribute therapeutic and prophylactic products related to LHRH antagonist compounds, for uses in the biomedical field, including oncology and reproductive endocrinology treatments, including breast and prostate cancer, endometriosis, uterine fibroid, fertility, polycystic ovarian disease and precocious puberty.

The provided text describes an amendment to a patent license agreement for LHRH antagonist compounds, which are therapeutic and prophylactic products used in reproductive endocrinology. The document highlights RoyaltyStat® as a database service utilized by professionals for valuing these intellectual property assets through royalty rate analytics. This commercial and legal framework supports the development and distribution of treatments for various conditions, including endometriosis. Relevance to endometriosis: listed as one indication for LHRH antagonist compounds, though the paper's main focus is on licensing agreements and data valuation services rather than clinical research.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works